Kaku Nakano Selected Research

pitavastatin (itavastatin)

5/2022	Pitavastatin-Incorporated Nanoparticles for Chronic Limb Threatening Ischemia: A Phase I/IIa Clinical Trial.
1/2022	Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apoe-/- Mice.
1/2021	Nanoparticle-Mediated Simultaneous Targeting of Mitochondrial Injury and Inflammation Attenuates Myocardial Ischemia-Reperfusion Injury.
3/2020	Therapeutic Arteriogenesis/Angiogenesis for Peripheral Arterial Disease by Nanoparticle-Mediated Delivery of Pitavastatin into Vascular Endothelial Cells.
1/2020	Simultaneous targeting of mitochondria and monocytes enhances neuroprotection against ischemia-reperfusion injury.
11/2018	Nanoparticle-Mediated Targeting of Pitavastatin to Small Pulmonary Arteries and Leukocytes by Intravenous Administration Attenuates the Progression of Monocrotaline-Induced Established Pulmonary Arterial Hypertension in Rats.
8/2017	Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Left Ventricular Remodeling After Acute Myocardial Infarction by Inhibiting Monocyte-Mediated Inflammation.
1/2016	A Translational Study of a New Therapeutic Approach for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin into Reperfused Myocardium Reduces Ischemia-Reperfusion Injury in a Preclinical Porcine Model.
1/2015	A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model.
2/2014	Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kaku Nakano Research Topics

Disease

20	Inflammation (Inflammations) 01/2021 - 09/2006
9	Myocardial Infarction 01/2021 - 01/2015
7	Ischemia 01/2021 - 06/2009
7	Reperfusion Injury 01/2020 - 01/2015
7	Neointima 01/2011 - 09/2006
5	Atherosclerosis 01/2022 - 09/2006
5	Myocardial Ischemia (Ischemic Heart Diseases) 01/2021 - 01/2015
5	Infarction (Infarctions) 01/2019 - 01/2016
5	Rupture 01/2018 - 01/2012
5	Atherosclerotic Plaque (Atheroma) 09/2017 - 10/2007
4	Ventricular Remodeling 08/2017 - 01/2016
3	Chronic Limb-Threatening Ischemia 05/2022 - 10/2012
3	Pathologic Constriction (Stenosis) 01/2013 - 12/2007
2	Peripheral Arterial Disease 03/2020 - 10/2012
2	Pulmonary Arterial Hypertension 11/2018 - 05/2009
2	Acute Coronary Syndrome 01/2018 - 01/2011
2	Heart Failure 08/2017 - 10/2012
2	Thrombosis (Thrombus) 01/2013 - 01/2011
2	Vascular Remodeling 02/2011 - 05/2009
2	Vascular Diseases (Vascular Disease) 01/2008 - 09/2006
1	Abdominal Aortic Aneurysm 01/2022
1	Brain Ischemia (Cerebral Ischemia) 01/2020
1	Ischemic Stroke 01/2020
1	Metabolic Diseases (Metabolic Disease) 11/2017
1	No-Reflow Phenomenon 01/2016
1	Left Ventricular Dysfunction 01/2015
1	Hypertension (High Blood Pressure) 02/2011
1	Cardiovascular Diseases (Cardiovascular Disease) 04/2009
1	Hemorrhage 12/2006

Drug/Important Bio-Agent (IBA)

13	pitavastatin (itavastatin)FDA Link 05/2022 - 08/2010
10	Therapeutic UsesIBA 01/2021 - 01/2012
7	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2018 - 06/2009
6	Apolipoproteins E (ApoE)IBA 01/2022 - 10/2007
5	Angiotensin IIIBA 01/2022 - 10/2007
5	LipidsIBA 01/2017 - 09/2006
5	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 02/2014 - 10/2007
4	Pioglitazone (Actos)FDA Link 01/2019 - 10/2012
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2021 - 02/2016
3	Mitochondrial Permeability Transition PoreIBA 01/2021 - 02/2016
3	SolutionsIBA 01/2019 - 11/2016
3	MonocrotalineIBA 11/2018 - 05/2009
2	Polylactic Acid-Polyglycolic Acid CopolymerIBA 05/2022 - 02/2014
2	ApolipoproteinsIBA 01/2022 - 02/2014
2	glycolic acid (glycolate)IBA 01/2021 - 01/2016
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 10/2007
2	Pharmaceutical PreparationsIBA 01/2017 - 10/2012
2	OxysterolsIBA 10/2016 - 01/2012
2	Matrix Metalloproteinases (MMPs)IBA 03/2016 - 01/2012
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 03/2016 - 10/2012
2	FibrinIBA 01/2013 - 12/2006
2	CholesterolIBA 01/2012 - 01/2008
2	Platelet-Derived Growth FactorIBA 01/2011 - 01/2008
2	Imatinib Mesylate (Gleevec)FDA Link 01/2011 - 09/2008
2	NF-kappaB decoyIBA 05/2009 - 12/2006
2	azelnidipineIBA 01/2008 - 09/2006
1	CC ChemokinesIBA 01/2021
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/2020
1	Cyclophilins (Cyclophilin)IBA 01/2020
1	ethyl 6- (N- (2- chloro- 4- fluorophenyl)sulfamoyl)cyclohex- 1- ene- 1- carboxylateIBA 01/2019
1	Toll-Like Receptor 4IBA 01/2019
1	PPAR gammaIBA 01/2019
1	HMGB1 Protein (HMG1)IBA 01/2019
1	CytokinesIBA 01/2019
1	Sildenafil Citrate (Viagra)FDA Link 11/2018
1	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 01/2018
1	gamma-oryzanolIBA 11/2017
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 08/2017
1	AntioxidantsIBA 01/2017
1	Oxidoreductases (Dehydrogenase)IBA 01/2017
1	Coenzyme A (CoA)IBA 01/2017
1	Irbesartan FDA LinkGeneric 11/2016
1	Peptide Hydrolases (Proteases)FDA Link 03/2016
1	Biomarkers (Surrogate Marker)IBA 03/2016
1	poly(lactide) (polylactic acid)IBA 01/2016
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 02/2014
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 02/2014
1	GelatinasesIBA 02/2014
1	AS resinIBA 01/2013
1	Sirolimus (Rapamycin)FDA Link 01/2013
1	Dietary CholesterolIBA 01/2012
1	Ezetimibe (Zetia)FDA Link 01/2012
1	Phosphotransferases (Kinase)IBA 01/2011
1	PDGF receptor tyrosine kinaseIBA 01/2011
1	NF-kappa B (NF-kB)IBA 05/2009
1	MetalsIBA 04/2009
1	Amlodipine (Norvasc)FDA LinkGeneric 01/2008
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2008
1	Receptor for Advanced Glycation End ProductsIBA 10/2007
1	LigandsIBA 10/2007
1	Chemotactic FactorsIBA 10/2007
1	Type 1 Angiotensin ReceptorIBA 10/2006

Therapy/Procedure

8	Therapeutics 01/2021 - 10/2012
8	Stents 01/2013 - 09/2006
5	Intravenous Administration 01/2019 - 02/2014
3	Intramuscular Injections 03/2020 - 06/2009
2	Drug-Eluting Stents 01/2013 - 01/2011
1	Ligation 01/2019
1	Drug Therapy (Chemotherapy) 01/2018
1	Splenectomy 08/2017
1	Catheters 10/2007